349 related articles for article (PubMed ID: 15779421)
41. Clinical experience with acarbose as first line therapy in NIDDM.
Fölsch UR
Clin Invest Med; 1995 Aug; 18(4):312-7. PubMed ID: 8549018
[TBL] [Abstract][Full Text] [Related]
42. [Effects of nateglinide in impaired glucose tolerance subjects].
Hirose T
Nihon Rinsho; 2005 Feb; 63 Suppl 2():438-43. PubMed ID: 15779419
[No Abstract] [Full Text] [Related]
43. [Pathophysiological conditions progressing from impaired glucose tolerance: coronary artery disease (ischemic heart disease)].
Tomono S; Uchiyama T; Ohyama Y
Nihon Rinsho; 2005 Feb; 63 Suppl 2():255-9. PubMed ID: 15779382
[No Abstract] [Full Text] [Related]
44. Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation.
Rudovich NN; Weickert MO; Pivovarova O; Bernigau W; Pfeiffer AF
Diabetes Technol Ther; 2011 Jun; 13(6):615-23. PubMed ID: 21488802
[TBL] [Abstract][Full Text] [Related]
45. Mulberry leaf extract reduces postprandial hyperglycemia with few side effects by inhibiting α-glucosidase in normal rats.
Kim GN; Kwon YI; Jang HD
J Med Food; 2011; 14(7-8):712-7. PubMed ID: 21631361
[TBL] [Abstract][Full Text] [Related]
46. Acarbose for patients with hypertension and impaired glucose tolerance.
González-Clemente JM; Ortega-Martínez de Victoria E; Giménez-Palop O; Mauricio D
JAMA; 2003 Dec; 290(23):3067; author reply 3067-9. PubMed ID: 14679263
[No Abstract] [Full Text] [Related]
47. Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.
Hanefeld M; Karasik A; Koehler C; Westermeier T; Chiasson JL
Diab Vasc Dis Res; 2009 Jan; 6(1):32-7. PubMed ID: 19156626
[TBL] [Abstract][Full Text] [Related]
48. Pioglitazone for diabetes prevention in impaired glucose tolerance.
DeFronzo RA; Tripathy D; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Clement SC; Henry RR; Hodis HN; Kitabchi AE; Mack WJ; Mudaliar S; Ratner RE; Williams K; Stentz FB; Musi N; Reaven PD;
N Engl J Med; 2011 Mar; 364(12):1104-15. PubMed ID: 21428766
[TBL] [Abstract][Full Text] [Related]
49. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.
Hanefeld M; Chiasson JL; Koehler C; Henkel E; Schaper F; Temelkova-Kurktschiev T
Stroke; 2004 May; 35(5):1073-8. PubMed ID: 15073402
[TBL] [Abstract][Full Text] [Related]
50. [Info-Meeting. Pharmacologic prevention of the progression from impaired glucose tolerance to type 2 diabetes: favorable effects of metformin and acarbose].
Scheen AJ
Rev Med Liege; 2001 Oct; 56(10):727-30. PubMed ID: 11765586
[TBL] [Abstract][Full Text] [Related]
51. [Therapies for newly-onset diabetic patients].
Kawamori R
Nihon Rinsho; 2005 Feb; 63 Suppl 2():525-32. PubMed ID: 15779435
[No Abstract] [Full Text] [Related]
52. Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders.
Yamagishi S; Matsui T; Ueda S; Fukami K; Okuda S
Curr Drug Metab; 2009 Feb; 10(2):159-63. PubMed ID: 19275550
[TBL] [Abstract][Full Text] [Related]
53. Effect of acarbose on vascular disease in patients with abnormal glucose tolerance.
Hanefeld M; Schaper F; Koehler C
Cardiovasc Drugs Ther; 2008 Jun; 22(3):225-31. PubMed ID: 18309462
[TBL] [Abstract][Full Text] [Related]
54. [Effect of pioglitazone, one of TZDs, on IGT-patients].
Kobayashi M
Nihon Rinsho; 2005 Feb; 63 Suppl 2():462-70. PubMed ID: 15779423
[No Abstract] [Full Text] [Related]
55. [Acarbose for prevention of diabetes mellitus. STOP-NIDDM]].
Windler E
Internist (Berl); 2003 Apr; 44(4):491-3. PubMed ID: 12914407
[No Abstract] [Full Text] [Related]
56. α-Glucosidase inhibitory effect of resveratrol and piceatannol.
Zhang AJ; Rimando AM; Mizuno CS; Mathews ST
J Nutr Biochem; 2017 Sep; 47():86-93. PubMed ID: 28570943
[TBL] [Abstract][Full Text] [Related]
57. [Optimal drug therapy of glucose intolerance is a guarantee of successful prevention of type 2 diabetes mellitus].
Mkrtumian AM
Ter Arkh; 2002; 74(12):86-9. PubMed ID: 12577852
[No Abstract] [Full Text] [Related]
58. [Management of blood glucose--target of the management and its practice].
Ishibashi S
Nihon Rinsho; 2006 Nov; 64(11):2089-94. PubMed ID: 17087301
[TBL] [Abstract][Full Text] [Related]
59. [Postprandial hyperglycemia. II. Pharmacological approaches].
Scheen AJ; Letiexhe MR; Geronooz I; Paquot N; Jandrain B
Rev Med Liege; 2002 Apr; 57(4):196-201. PubMed ID: 12073790
[TBL] [Abstract][Full Text] [Related]
60. Acarbose for patients with hypertension and impaired glucose tolerance.
Bridges CM
JAMA; 2003 Dec; 290(23):3066-7; author reply 3067-9. PubMed ID: 14679261
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
